Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798587 | 0.89 | HRH3 (0.71) | HRH3KCNH2RECQL | |
| SCHEMBL63877 | 0.82 | USP2 (0.53) | RECQLHPGD | |
| SCHEMBL2799922 | 0.81 | HRH3 (0.55) | HRH3KCNH2RECQLHPGD | |
| SCHEMBL24433551 | 0.80 | HRH3 (0.57) | HRH3KCNH2 | |
| SCHEMBL2800743 | 0.79 | HRH3 (0.59) | HRH3KCNH2 | |
| SCHEMBL16356995 | 0.78 | USP2 (0.50) | RECQLHPGD | |
| SCHEMBL346826 | 0.78 | HPGD (0.47) | HRH3RECQLHPGD | |
| SCHEMBL20641622 | 0.78 | USP2 (0.50) | RECQLHPGD | |
| SCHEMBL26873336 | 0.78 | USP2 (0.50) | RECQLHPGD | |
| SCHEMBL8217782 | 0.78 | USP2 (0.50) | RECQLHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| EP-4244208-A1 | A MAGL INHIBITOR | H. Lundbeck A/S (DK) | 2023-09-20 | — | — | EP | disclosed |
| CN-116547274-A | MAGL inhibitors | H.隆德贝克有限公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022101412-A1 | A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | WO | disclosed |
| US-20220153721-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | US | disclosed |
| WO-2022101412-A1 | A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018120-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | HRH3 4372/4885KCNH2 2917/4885RECQL 4737/4885 |
| US-20220153721-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | HRH3 4372/4885KCNH2 2917/4885RECQL 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.